Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 22:21 | 2026-06-29 | PGEN | PRECIGEN, INC. | Shah Rutul R | Officer | OPT+S | $5.85 | 42,924 | $251,105 | 497,751 |
| 2026-07-01 22:22 | 2026-06-29 | PGEN | PRECIGEN, INC. | Thomasian Harry Jr. | Officer | SELL | $5.57 | 200,000 | $1,113,140 | 354,535 |
| 2026-07-01 22:29 | 2026-07-01 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | OPT+S | $51.51 | 9,000 | $463,621 | 73,389 |
| 2026-07-01 22:34 | 2026-06-29 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Director | OPT+S | $34.38 | 17,750 | $610,252 | 16,474 |
| 2026-07-01 22:19 | 2026-06-29 | PGEN | PRECIGEN, INC. | Sabzevari Helen | Officer | OPT+S | $5.89 | 346,836 | $2,042,864 | 3,768,872 |
| 2026-07-01 20:30 | 2026-06-29 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $123.51 | 5,500 | $679,305 | 58,117 |
| 2026-07-01 20:31 | 2026-06-30 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $541.00 | 9,500 | $5,139,542 | 40,513 |
| 2026-07-01 20:34 | 2026-06-29 | AKBA | Akebia Therapeutics, Inc. | Ostrowski Erik | Officer | SELL | $1.11 | 56,019 | $62,181 | 616,616 |
| 2026-07-01 20:16 | 2026-06-30 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Director, Officer | BUY | $1.93 | 2,531 | $4,885 | 21,729 |
| 2026-07-01 20:17 | 2026-06-30 | PCSA | Processa Pharmaceuticals, Inc. | SKIBSTED RUSSELL | Officer | BUY | $1.93 | 3,277 | $6,325 | 16,689 |
| 2026-07-01 20:19 | 2026-07-01 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | Director, Officer | BUY | $1.93 | 3,057 | $5,900 | 15,492 |
| 2026-07-01 20:19 | 2026-06-30 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Officer | BUY | $1.93 | 2,106 | $4,065 | 13,113 |
| 2026-07-01 20:05 | 2026-06-29 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | Director, Officer | SELL | $39.83 | 8,220 | $327,398 | 548,027 |
| 2026-07-01 17:39 | 2026-06-30 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | Director, Officer, 10% owner | BUY | $20.00 | 12,500 | $250,000 | 3,688,424 |
| 2026-07-01 17:41 | 2026-06-30 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% owner | BUY | $18.32 | 50,000 | $916,000 | 3,186,576 |
| 2026-07-01 14:30 | 2026-06-29 | ADIL | ADIAL PHARMACEUTICALS, INC. | Coastlands Capital LP | 10% owner | BUY | $2.60 | 25,000 | $65,000 | 373,322 |
| 2026-07-01 00:38 | 2026-06-26 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Director | SELL | $34.46 | 1,638,163 | $56,444,053 | 1,748,403 |
| 2026-07-01 00:30 | 2026-06-26 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Director | SELL | $34.32 | 1,438,163 | $49,354,015 | 13,689,166 |
| 2026-06-30 23:50 | 2026-06-29 | CLYM | Climb Bio, Inc. | Brennan Aoife | Director, Officer | OPT+S | $13.17 | 30,902 | $406,979 | 87,731 |
| 2026-06-30 23:59 | 2026-06-26 | ROIV | Roivant Sciences Ltd. | QVT Financial LP | SELL | $34.32 | 1,438,163 | $49,354,015 | 13,689,166 | |
| 2026-06-30 23:23 | 2026-06-26 | GALT | GALECTIN THERAPEUTICS INC | Jamil Khurram | Officer | OPT+S | $5.04 | 52,037 | $262,084 | 0 |
| 2026-06-30 23:24 | 2026-06-26 | GALT | GALECTIN THERAPEUTICS INC | Shlevin Harold H. | Director | OPT+S | $5.03 | 30,000 | $150,891 | 6,500 |
| 2026-06-30 23:05 | 2026-06-26 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Director | SELL | $21.23 | 504,695 | $10,712,555 | 975,931 |
| 2026-06-30 23:01 | 2026-06-29 | SEPN | Septerna, Inc. | Shaikhly Samira | Officer | OPT+S | $35.18 | 2,178 | $76,622 | 793 |
| 2026-06-30 22:41 | 2026-06-26 | MLYS | Mineralys Therapeutics, Inc. | Warren Eric | Officer | OPT+S | $25.90 | 104,124 | $2,696,322 | 38,400 |
| 2026-06-30 22:41 | 2026-06-30 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer | SELL | $26.14 | 75,000 | $1,960,605 | 614,321 |
| 2026-06-30 21:45 | 2026-06-26 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | Officer | OPT+S | $72.50 | 300 | $21,750 | 54,324 |
| 2026-06-30 21:48 | 2026-06-26 | IONS | IONIS PHARMACEUTICALS INC | Schneider Eugene | Officer | OPT+S | $81.05 | 26,000 | $2,107,196 | 77,114 |
| 2026-06-30 21:48 | 2026-06-26 | IONS | IONIS PHARMACEUTICALS INC | O'NEIL PATRICK R. | Officer | SELL | $80.00 | 3,069 | $245,520 | 61,470 |
| 2026-06-30 21:48 | 2026-06-26 | IONS | IONIS PHARMACEUTICALS INC | Baroldi Joseph | Officer | OPT+S | $80.16 | 5,635 | $451,699 | 4,669 |
| 2026-06-30 21:49 | 2026-06-26 | IRON | Disc Medicine, Inc. | Khara Rahul | Officer | OPT+S | $75.00 | 2,500 | $187,500 | 52,173 |
| 2026-06-30 21:20 | 2026-06-26 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer | OPT+S | $85.26 | 8,130 | $693,152 | 60,137 |
| 2026-06-30 21:06 | 2026-06-26 | QURE | uniQure N.V. | Abi-Saab Walid | Officer | SELL | $46.86 | 1,434 | $67,197 | 168,235 |
| 2026-06-30 20:40 | 2026-06-29 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $545.80 | 9,500 | $5,185,133 | 40,513 |
| 2026-06-30 20:30 | 2026-06-26 | FULC | Fulcrum Therapeutics, Inc. | Ezekowitz Alan | Director | SELL | $3.65 | 18,000 | $65,614 | 10,927 |
| 2026-06-30 20:09 | 2026-06-26 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen | Officer | SELL | $482.50 | 596 | $287,570 | 15,337 |
| 2026-06-30 20:14 | 2026-06-29 | ANIP | ANI PHARMACEUTICALS INC | CAREY STEPHEN P. | Officer | SELL | $84.12 | 2,850 | $239,742 | 177,543 |
| 2026-06-30 20:01 | 2026-06-26 | PRQR | ProQR Therapeutics N.V. | Filius Bart | Director | BUY | $1.54 | 150,000 | $231,000 | 150,000 |
| 2026-06-30 01:53 | 2026-06-25 | LEGN | Legend Biotech Corp | Huang Ying | Director, Officer | SELL | $14.78 | 5,566 | $82,265 | 241,872 |
| 2026-06-30 01:30 | 2026-06-25 | CAPR | CAPRICOR THERAPEUTICS, INC. | Bergmann Anthony | Officer | OPT+S | $30.38 | 24,100 | $732,158 | 11,223 |
| 2026-06-30 01:30 | 2026-06-25 | CAPR | CAPRICOR THERAPEUTICS, INC. | Krasney Karen | Officer | OPT+S | $30.38 | 24,100 | $732,158 | 30,547 |
| 2026-06-29 23:56 | 2026-06-25 | BOLD | Boundless Bio, Inc. | TANG KEVIN | 10% owner | BUY | $2.50 | 286,333 | $714,773 | 2,533,845 |
| 2026-06-29 23:07 | 2026-06-29 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.30 | 157,084 | $47,125 | 143,199 |
| 2026-06-29 22:41 | 2026-06-25 | PHVS | Pharvaris N.V. | Lesage Anne | Officer | OPT+S | $35.12 | 4,600 | $161,560 | 131,669 |
| 2026-06-29 22:23 | 2026-06-25 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Director, Officer | OPT+S | $34.11 | 1,000,000 | $34,105,000 | 18,677,617 |
| 2026-06-29 22:05 | 2026-06-24 | CYTK | CYTOKINETICS INC | Lee Sung | Officer | OPT+S | $82.30 | 38,730 | $3,187,479 | 63,221 |
| 2026-06-29 22:18 | 2026-06-25 | PHVS | Pharvaris N.V. | Lu Peng | Officer | OPT+S | $34.30 | 29,700 | $1,018,832 | 65,631 |
| 2026-06-29 22:18 | 2026-06-29 | PHVS | Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus | Director | SELL | $35.10 | 2,400 | $84,250 | 352,767 |
| 2026-06-29 22:00 | 2026-06-26 | ACAD | ACADIA PHARMACEUTICALS INC | Kihara James | Officer | SELL | $26.08 | 11,421 | $297,912 | 13,088 |
| 2026-06-29 22:00 | 2026-06-26 | ATAI | AtaiBeckley Inc. | Kochendoerfer Gerd | Officer | OPT+S | $5.00 | 50,000 | $250,000 | 0 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.